Fact CheckerSign in

NCT07481877Not yet recruiting

Portosystemic Shunt-associated Pulmonary Hypertension Multi-center Prospective Cohort Study

Source: ClinicalTrials.gov · Last updated 19 Mar 2026

Brief summary (registry, in English)

This study aims to establish a multi-center registry cohort of portosystemic shunt-associated pulmonary hypertension, with the goal of clarifying the epidemiology, clinical features, phenotypic classification, response to targeted therapy, and prognostic outcomes in patients with portosystemic shunt-associated pulmonary hypertension.

Status (registry)
Not yet recruiting
Study type
Observational
Enrollment
300 (estimated)
First submitted
8 Mar 2026
Start date
1 Apr 2026
Primary completion date
1 Apr 2031
Lead sponsor
Chinese Pulmonary Vascular Disease Research Group
NCT number
NCT07481877

What you commit to

  • Study type: Observational
  • Planned participants: 300
  • From 1 Apr 2026 to the primary completion date, 1 Apr 2031
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Transjugular intrahepatic portosystemic shunt (TIPS) placement within the previous month.
  • Participation in other interventional clinical trials (drug or device) within the last 3 months.

Other illness

  • Active extrahepatic malignancy.

Other

  • PH caused by other reasons
  • Hepatocellular carcinoma (HCC) exceeding the Milan criteria.
  • Pregnancy or lactation.

Who the study is looking for

  • Age ≥ 18 years.
  • Diagnosis of Portosystemic Shunts:Imaging evidence suggestive of portosystemic shunts (congenital or acquired) or unequivocal clinical signs of portal hypertension (e.g., splenomegaly, varices).
  • Diagnosis of Pulmonary Hypertension (PH):
    • Confirmed by Right Heart Catheterization (RHC): mPAP \> 20 mmHg; OR
    • Highly suspected by Echocardiography: Peak TRV \> 3.4 m/s or compliant with ESC/ERS guidelines for high probability of PH (Note: RHC is encouraged for all enrolled patients).
  • Signed informed consent and willingness to strictly adhere to the follow-up schedule.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.